ArticleJournal of the American Heart Association2022
Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239 234 Patients During 2005 to 2018 in the United States.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06454045 (Evaluation of Platelet Aggregability in Patients With Previous Acute Myocardial Infarction or Concomitant Lower Extremity Peripheral Artery Disease), which is not on this map. Cited by 64 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Platelet Aggregability in Patients With Previous Acute Myocardial Infarction or Concomitant Lower Extremity Peripheral Artery Disease
Who cites it
64 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Latin-American guidelines of recommendations at discharge from an acute coronary syndrome.Archivos de cardiologia de Mexico · 2024Guideline
- Novel Low-Density Lipoprotein Cholesterol Reduction Therapies for the Secondary Prevention of Cardiovascular Disease.Reviews in cardiovascular medicine · 2023Pooled it
- Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis.Indian heart journalPooled it
- Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial.Journal of the American Heart Association · 2026Trial
- Sex differences in risk factor control and medication adherence post-ACS: insights from the TEXTMEDS randomised clinical trial.Open heart · 2026Trial
- Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial.PharmacoEconomics · 2026Trial
- Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition.European heart journal. Cardiovascular pharmacotherapy · 2023Trial
- Premature coronary artery disease in women: sex-specific risk factors, pathogenetic mechanisms and clinical implications.Annals of medicine · 2026Review
- Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2026Review
- Prognosis by Renal Function With or Without Percutaneous Coronary Intervention in Non-ST-Segment Elevation Myocardial Infarction.JACC. Asia · 2026Article
- The roles of quantitative doppler echocardiography in optimizing guideline-directed medical therapy in Post-STEMI patients.The international journal of cardiovascular imaging · 2026Review
- Patient Stratification for Improving Acute Chest Pain Management and Mitigating Emergency Department Crowding: Machine Learning Model Development and Validation.JMIR medical informatics · 2026Article
- Major cardiovascular events in Japanese patients with acute and chronic coronary syndrome.Open heart · 2026Article
- PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study.European heart journal · 2026Observational
- Prevalence and Predictors of Lipoprotein(a) Measurement in Younger Patients Following ST-Elevation Myocardial Infarction.CJC open · 2026Article
- Dynamic Risk Trajectories for Sudden Cardiac Arrest: The Role of Recurrent Cardiovascular Events.Journal of the American Heart Association · 2026Observational
- Prognostic value of left atrial reservoir strain for major adverse cardiovascular events in coronary artery disease.Journal of echocardiography · 2026Review
- [Austrian lipid consensus : Interdisciplinary evidence-based recommendations on prevention and treatment of lipid-associated diseases from 15 medical specialist societies].Wiener klinische Wochenschrift · 2026Article
- The Obesity Paradox in Major Adverse Cardiovascular Events After PCI for Acute Coronary Syndrome: A Narrative Review.Journal of cardiovascular development and disease · 2026Review
- A polypill strategy for lipid lowering and anti-platelet therapy after acute coronary syndrome: A pilot randomized controlled trial.American journal of preventive cardiology · 2026Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Patients with acute coronary syndrome (ACS) are recognized by guidelines as remaining at high risk for adverse outcomes. Evidence from contemporary, representative ACS populations in a clinical practice setting is necessary to identify subgroups and strategies for improving patient outcomes. We aimed to describe event rates and risk factors in an ACS population over prolonged follow-up for cardiovascular end points. Methods and Results We identified 239 234 patients in the Optum Research Database (57.2% men; mean [standard deviation] age, 69.2 [12.2] years) with evidence of an ACS hospitalization (index ACS) during January 1, 2005 through December 30, 2018. Subgroups were based on index ACS event (myocardial infarction/unstable angina and revascularization status) and the Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention. The 5-year event rate for the primary end point representing nonfatal myocardial infarction, nonfatal ischemic stroke, and cardiovascular death was 33.4% (95% CI, 33.1%-33.7%;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.